|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
FY2019
12 months to Dec 31, 2019
|
FY2018
12 months to Dec 31, 2018
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation | |||||
| Stock-based compensation expense | |||||
| Fair value of warrants issued in excess of proceeds received | |||||
| Issuance costs allocated to warrants | |||||
| Change in fair value of warrant liabilities | |||||
| Net amortization of premium paid on marketable securities | |||||
| Changes in operating assets and liabilities: | |||||
| Decrease (increase) in prepaid expenses and other current and non-current assets | |||||
| Increase (decrease) in accounts payable, accrued liabilities and other liabilities | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities | |||||
| Purchases of marketable securities | |||||
| Sales of marketable securities | |||||
| Proceeds from maturities of marketable securities | |||||
| Purchases of property and equipment | |||||
| Net cash provided by (used in) investing activities | |||||
| Cash flows from financing activities | |||||
| Proceeds from issuance of equity securities | |||||
| Payment of financing costs of securities sold | |||||
| Proceeds from exercise of warrants | |||||
| Net cash provided by financing activities | |||||
| Net (decrease) increase in cash and cash equivalents | |||||
| Cash and cash equivalents at beginning of period | |||||
| Cash and cash equivalents at end of period | |||||
| Supplemental disclosures of cash flow information: | |||||
| Issuance of warrants to purchase common stock | |||||
Loading...
